TRENDING TOPICS
3286 articles found for "investing"
While Eli Lilly and Novo Nordisk dominate headlines with obesity drugs, traditional pharmaceutical giants like Pfizer, Merck, and Johnson & Johnson are trading at historically low valuations.
Spot Bitcoin ETFs posted nearly $1 billion in single-day outflows on January 29, erasing January gains. BlackRock's IBIT and Fidelity's FBTC led the exodus as crypto markets sold off.
Silver hit a record $121.64 per ounce this week, surging 65% in January alone. Solar panels, AI chips, and flight from fiat currencies have created an explosive mix for the white metal.
The private credit market has ballooned to over $2 trillion with projections for $4 trillion by 2030. Now, a string of defaults and dropped safeguards has Wall Street on edge.
Tech giants will spend over $400 billion on AI data centers in 2026, creating the largest construction boom in a generation. Here's how it's transforming the industry.
Reddit stock has soared 567% since its March 2024 IPO, making it one of the best-performing recent IPOs. Here's how the social media company achieved profitability and where it goes next.
Nvidia's data center chip orders have reached $275 billion as partnerships with OpenAI, Anthropic, and resumed China sales fuel explosive growth. What investors should know.
Bitcoin tumbled 6% over the weekend to fall below $79,000 as the dollar strengthened following Kevin Warsh's Fed chair nomination. Analysts see continued volatility ahead.
Gold touched $5,608 this week, capping a 100% gain over 12 months. Central bank buying, dollar weakness, and geopolitical uncertainty drive the historic surge.
Phillips 66's refining unit posted a $775 million quarterly loss as crack spreads collapsed from 2022-2023 highs. The results mark a turning point for energy investors.
Costco's September 2024 membership fee increase is now flowing through earnings, with fee revenue up 14% to $1.33 billion in the most recent quarter.
AbbVie announced a 5.5% dividend increase to $1.73 per share, extending its streak of consecutive annual raises to 53 years as the drugmaker navigates life after Humira's patent cliff.